NCT00898313 Molecular Predictors of Cancer in Patients at High Risk of Lung Cancer
| NCT ID | NCT00898313 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Vanderbilt-Ingram Cancer Center |
| Condition | Lung Cancer |
| Study Type | OBSERVATIONAL |
| Enrollment | 4,000 participants |
| Start Date | 2003-12 |
| Primary Completion | 2027-01-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 4,000 participants in total. It began in 2003-12 with a primary completion date of 2027-01-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
RATIONALE: Using samples of blood, urine, sputum, and lung tissue from patients at high risk of cancer for laboratory studies may help doctors learn more about changes that may occur in DNA and identify biomarkers related to cancer. PURPOSE: This research study is looking at molecular predictors of cancer in patients at high risk of lung cancer.
Eligibility Criteria
Inclusion Criteria: -All adults referred to Vanderbilt Medical Center, Veterans Administration Medical Center, St. Thomas Hospital and Meharry Medical Center for evaluation of signs or symptoms of lung cancer. Exclusion Criteria: * Inability to provide informed consent * Minors * Pregnant women
Contact & Investigator
Vanderbilt Ingram Clinical Trials Information Program
📞 1-800-811-8480
Fabien Maldonado, MD
STUDY CHAIR
Vanderbilt-Ingram Cancer Center
Frequently Asked Questions
Who can join the NCT00898313 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Lung Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT00898313 currently recruiting?
Yes, NCT00898313 is actively recruiting participants. Visit ClinicalTrials.gov or contact Vanderbilt-Ingram Cancer Center to inquire about joining.
Where is the NCT00898313 trial being conducted?
This trial is being conducted at Nashville, United States, Nashville, United States.
Who is sponsoring the NCT00898313 clinical trial?
NCT00898313 is sponsored by Vanderbilt-Ingram Cancer Center. The principal investigator is Fabien Maldonado, MD at Vanderbilt-Ingram Cancer Center. The trial plans to enroll 4,000 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.